Previous reports have shown that, in certain cell types, p21 , which plays a central role in cell proliferation, can be activated by HTLV-I Tax protein and by TPA. Tax and TPA are also known to stimulate HTLV-I gene expression. Since cell proliferation has a major impact on HTLV-I replication, it was of interest to investigate their effect on p21
Introduction
The cyclin-dependent kinase (CDK) inhibitor p21 plays a dual role in cell growth control. It exists as a component of complexes that also contain D and E cyclins, CDKs and the proliferating cell nuclear antigen (PCNA), an accessory subunit which is essential for the DNA replication and DNA repair functions of the DNA polymerases d and e (Zhang et al., 1993; Warbrick, 2000) . Depending on its stoichiometry relative to the other components in these complexes, p21
WAF-1 may act either to promote or to arrest cell proliferation. At low to intermediate levels, p21 promotes cell cycle progression by acting as an assembly factor that enhances the association of the CDKs to the cyclins and targets them to the nucleus (Zhang et al., 1994; LaBaer et al., 1997) . On the other hand, at high levels, multiple p21
WAF-1 molecules bind to these complexes and act to interfere with the cell proliferation (Zhang et al., 1994; Harper et al., 1995; LaBaer et al., 1997; Boulaire et al., 2000) by inhibiting the activity of CDK2, CDK4 and CDK6 and arresting, thereby, the cell cycle progression (Harper et al., 1995; Niculescu et al., 1998) . In addition, under such conditions, p21
WAF-1 interacts with PCNA and inhibits, thereby, the DNA replication activity of the DNA polymerases d and e without interfering with their DNA repair function (Waga et al., 1994; Warbrick, 2000) .
The level of p21 WAF-1 protein is affected by diverse signaling stimuli promoting cell differentiation, cell cycle arrest or apoptosis, like phorbol esters (Biggs et al., 1996; Zezula et al., 1997; Biggs and Kraft (1999) ; Dempsey et al., 2000) , cytokines (Hobeika et al., 1997; Bellido et al., 1998) , growth factors (Datto et al., 1995; Decker, 1995; Billon et al., 1996; Li et al., 1998) and stress factors (Macleod et al., 1995; Namaba et al., 1995) , which exert their effect primarily by modulating the transcriptional expression of its encoding gene. The promoter of p21 WAF-1 gene contains binding sites for various transcription factors (Gartel and Tyner, 1999) . Of particular note in this context is the pivotal role of Sp1, which has six recognition sites residing in the p21 WAF-1 promoter between nucleotides -120 and À50 relative to the transcription starting point (Moustakas and Kardassis, 1998; Lu et al., 2000; Koutsodontis et al., 2001) , through which it mediates p21 WAF-1 activation by certain external signals (Gartel and Tyner, 1999) . In addition, Sp1 facilitates p21 WAF-1 activation by certain other transcription factors through physical interaction with them. Such an interaction was shown for p53 (Koutsodontis et al., 2001) , the androgen receptor (Lu et al., 2000) , the CREB-binding protein (CBP) (Gartel and Tyner, 1999) , the progesterone receptor (Owen et al., 1998) and members of the c-Jun (Kardassis et al., 1999) and Smad (Moustakas and Kardassis, 1998; Pardali et al., 2000) families.
12-O-tradecanoylphorbol-13-acetate (TPA) is a potent protein kinase C (PKC) activator and most of its biological effects are exerted through PKC-associated pathways (Mellor and Parker, 1998; Ron and Kazanietz, 1999) . The PKC family consists of at least 12 different isoforms that are classified into three groups; the conventional (cPKCs) that are activated by calcium and diacylglycerol (DAG), the novel (nPKCs) that are calcium-independent, but DAG-dependent and the atypical isoform (aPKCs) that are both calcium-and DAG-independent. These isoforms differ in terms of their cell type and subcellular distribution and the targets of their action. Notably, only cPKCs and the nPKCs, but not aPKCs, can be activated by TPA (Mellor and Parker, 1998) .
Extended exposure to TPA leads, in certain cell types, to a downregulation of the TPA-responsive PKCs (Lu et al., 1998; Isonishi et al., 2000) . In previous studies, we have demonstrated such a TPA-induced downregulation of cPKCs and nPKCs in the Jurkat human T-cell line (Mor-Vaknin et al., 1997; Torgeman et al., 2001a) . We have also shown that TPA activates the expression of HTLV-I and induces apoptosis in these cells (Torgeman et al., 2001a) . However, we have noted that both of these effects start only when the cells are already depleted of the TPA-responsive PKCs, or if PKC activity is blocked by specific inhibitors (Mor-Vaknin et al., 1997; Torgeman et al., 2001a, b) . It is, therefore, evident not only that, unlike most other biological effects of TPA, these particular effects do not require PKC but they are also rather antagonized by its activity.
PKC has been shown to activate, in certain cell lines, the expression of p21 WAF-1 (Biggs et al., 1996; Zezula et al., 1997; Biggs and Kraft (1999) ; Dempsey et al., 2000) . p21
WAF-1 has also been shown to be activated in some cell lines by the HTLV-I transactivator Tax protein (Cereseto et al., 1996; de La Fuente et al., 2000) . Since cell proliferation has a major impact on HTLV-I replication, it was of interest to examine the effect of these two HTLV-I activators on p21 WAF-1 expression in human T cells, which are the main target of this virus in human infection, and to elucidate their interrelationships.
The present study demonstrates that both Tax and  TPA stimulated p21 WAF-1 in human T cells through mechanisms that are independent of each other and that together they display an additive stimulation.
We also show that the stimulation by TPA is mediated by a PKC-dependent mechanism and that this mechanism is geared by specific PKC isoforms that induce the binding of Sp1-p53 complex to the second most upstream Sp1 site on the p21 WAF-1 promoter with no need for a direct binding of p53 to a p53 recognition site.
Results

TPA-induced PKC-dependent activation of p21
WAF-1 in HTLV-I infected and uninfected T cells
To elucidate the relationships between the activation of p21 WAF-1 by TPA and Tax, we examined, first, the effect of TPA on p21 WAF-1 expression in HTLV-I infected (SLB-I) and uninfected (Jurkat) T cells. Figure 1a shows that TPA elevated the level of p21 WAF-1 protein in both cell lines. Notably, the basal level of this protein without TPA treatment was much higher in the infected than in the uninfected cells, presumably due to its elevation by the viral Tax protein present in the infected cells. To confirm this presumption, we examined the effect of transfection of Tax-expressing vector on the level of WAF-1 in the extract of the total cell population. This elevation was prevented when Tax was cotransfected with the negative transdominant D58Tax mutant, thus confirming that it was specifically induced by Tax protein. It should be noted that since the employed vectors were uptaken by only a fraction of the transfected cell population, the real Tax-induced p21 WAF-1 elevation in this fraction was likely much higher and complied with the high basal p21 WAF-1 level observed in the infected SLB-I cells. Although most of the TPA-induced biological effects are exerted through PKC-associated pathways, we have previously shown that TPA stimulates HTLV-I LTR expression (Mor-Vaknin et al., 1997; Torgeman et al., 1999; Torgeman et al., 2001b) and induces apoptosis (Torgeman et al., 2001a) in Jurkat and certain other human T-cell lines, as well as in primary human lymphocytes (Torgeman et al., 2001a) , by PKC-independent mechanisms. Therefore, we investigated whether the TPA-induced stimulation of p21 required PKC activity by testing this effect in the presence of the PKC-specific inhibitor bisindolylmaleimide GF 109203X (BI) (Hingorani et al., 2000; Toullec et al., 1991) . Figure 1a demonstrates that BI almost completely diminished the stimulatory effect of TPA on p21 , indicating that PKC activity was essential for exerting this effect.
To further substantiate this notion, a reporter plasmid expressing luciferase through the complete p21 WAF-1 promoter (p21Luc) was transfected into Jurkat cells pretreated with TPA in the presence or absence of BI for 6 h before transfection. Figure 1c shows that in the absence of the inhibitor, TPA remarkably enhanced the reporter expression, whereas BI completely abolished this stimulation. BI alone had no effect on the reporter expression.
In accord with the effect of Tax on p21 WAF-1 protein level, Figure 1c shows that Tax also stimulates the expression of p21 promoter, whereas D58Tax abolishes this stimulation. D58Tax alone had no effect on this promoter. Figure 1c also shows that TPA and Tax together exhibit an additive stimulation, whereas BI reduces this stimulation to the level induced by Tax alone and D58Tax reduces it to the level induced by TPA alone. Together, these data indicate that the mechanisms of the effects of TPA and Tax on p21 WAF-1 are completely unrelated to each other.
Effect of different PKC isoforms on the expression of p21 WAF-1 promoter
To gain a better insight into the role of PKC in p21 activation by TPA, we examined the effect of different PKC isoforms on the expression of p21 WAF-1 promoter. This was carried out by cotransfection of the p21Luc reporter plasmid together with vectors expressing different constitutively active PKC isoforms in the presence or absence of the inhibitor BI. Figure 2a shows that PKCa and PKCe markedly stimulated p21Luc expression, whereas PKCZ inhibited this expression and the isoforms b1 and b2 were ineffective. BI abolished the effects of both the stimulatory and the inhibitory PKCs, thus verifying that these effects were, indeed, mediated by the activity of the transfected PKCs. These data indicate that different individual PKCs elicit different effects on p21 WAF-1 expression. A possible explanation for the TPA-induced stimulation of p21 WAF-1 is that the inhibitory PKCZ is probably not expressed in Jurkat cell or not activated by TPA in these cells. This possibility was addressed by treating these cells with TPA for increasing times and measuring the level of the above PKCs in their whole-cell extracts by Western blot analysis. Since TPA-responsive PKCs are downregulated following their activation by TPA (Lu et al., 1998) , the time-dependent decline of each examined PKC was taken as an indication of its activation. Figure 2b shows that all of the tested PKCs were present and were activated by TPA in these cells.
Another possibility is that when these isoforms are present together in an active state, the isoforms that stimulate p21
WAF-1 expression override the inhibitory effect of PKCZ. To test this possibility, p21Luc plasmid Previous studies have shown that in certain cell lines, TPA activates p21 WAF-1 expression through an Sp1 site (Biggs et al., 1996) , whereas in others, it exerts this effect through the AP-2 (Zeng et al., 1997) or the Smad (Biggs et al., 1996) sites. Since from previous reports Sp1 appeared to play a pivotal role in p21
WAF-1 regulation, we investigated whether in Jurkat cells the effect of TPA on this gene was mediated by the Sp1 sites. As shown in Figure 3a , there are six Sp1 recognition sites in the proximal region of the human p21 WAF-1 promoter (Moustakas and Kardassis, 1998; Lu et al., 2000; Koutsodontis et al., 2001) . To elucidate which of them mediates the stimulation of this promoter by TPA, we used plasmids expressing Luc through various p21 WAF-1 mutant promoters, each carrying an inactivating mutation in a different Sp1 site. These mutants were transfected into Jurkat cells pretreated with TPA for 6 h before transfection. Figure 3b . demonstrates that the mutation in the second most upstream Sp1 site [Sp1(2)] markedly reduced the basal Luc expression and completely diminished its stimulation by TPA. To verify that this mutation did not completely destroy the transcriptional activity of this promoter, we examined its response to p53 (see Figure 3a for the location of the p53 sites on this promoter). As shown in Figure 3c , this mutant was readily stimulated by the p53-expressing vector, confirming that it was transcriptionally functional. These data indicate that the Sp1(2) site is essential for the TPA effect on p21 WAF-1 in these cells.
PKC-dependent binding of nuclear proteins to Sp1(2) site
To substantiate the role of PKC and Sp1(2) site in p21 WAF-1 activation by TPA, we prepared four doublestranded oligonucleotides carrying the Sp1(1) and Sp1(2) sites at the following combinations: both wildtype (w.t.) sites (oligo 1), both mutant sites (oligo 2), w.t. Sp1(1) site and mutant Sp1(2) site (oligo 3) and mutant Sp1(1) site and w.t. Sp1(2) site (oligo 4). These oligos were incubated with nuclear extracts (15 mg protein) of Jurkat cells that were treated for 6 h with TPA in the absence or presence of the inhibitor BI. As control, similar reactions were run with extracts of untreated cells and cells treated with BI alone. The electrophoretic mobility analysis depicted in Figure 4b revealed that the nuclear proteins of the TPA-treated cells formed three complexes (represented by bands I, II and III) with oligos 1 and 4, but only two (bands II and III) with oligos 2 and 3, indicating that the slowest migrating complex (band I) was specifically formed on the Sp1(2) site. This conclusion was further supported by the competition data presented in Figure 4c , showing that the formation of complex I on oligo 1 could be competed out by 50-fold molar excess of unlabeled oligo 1 or 4 but not of oligos 2 and 3. The other two bands were unaffected by any of the competing oligos at 50-fold molar excess ( Figure 4c ) and only partially reduced by 250-fold excess (not shown), suggesting that were formed by some nonspecific proteins existing in the extracts in a vast amount. Notably, complex I was not formed, with either oligo 1 or oligo 4, by the extract of (Figure 4b) . Furthermore, the extract of untreated cells formed only the two nonspecific complexes, II and III with oligos 1 (Figure 4a ) and 4 (not shown). Together, these data indicate that the formation of complex I on the Sp1(2) site requires PKC activity. This PKC requirement and the formation of this complex exclusively on the Sp1(2) site correlate the Sp1(2) and PKC dependency of the p21 WAF-1 promoter activation by TPA observed in the above transfection experiments. This strict correlation strongly indicates that complex I mediates the TPA-induced p21 activation.
Activation of p21
WAF-1 by TPA is mediated by Sp1-p53 complex
To identify the nuclear factors involved in complex I formation, this complex was formed on oligo 4 and subjected to supershift analysis with various monoclonal antibodies. The results shown in Figure 4d demonstrate that this complex was supershifted by anti-Sp1 antibodies and by the pAb421 antibodies that recognize both w.t. and mutant forms of p53 protein. Notably, the supershift by the anti-p53 antibodies was significantly more prominent than that conferred by the anti-Sp1 antibodies. This may suggest that p53 protein exists in this complex at a higher molar quantity than the Sp1 protein, so that more molecules of anti-p53 antibodies bind to this complex than of the anti-Sp1 antibodies. Furthermore, addition of the anti-Sp1 and anti-p53 antibodies together resulted in even stronger supershift of this complex. This indicates that band I represents a single complex containing both Sp1 and p53 and rules out the possible argument that it might consist of two separate complexes with a similar electrophoretic migration, one that contains only Sp1 protein bound to the Sp1 site and the other containing only p53 protein, which might have bound nonspecifically to this oligo. No supershift of band I was detected with antialbumin antibodies, thus confirming the specificity of this assay.
Complex I contains both w.t.and mutant p53 proteins
Like several other human T-cell lines, Jurkat cells contain both w.t. and mutant forms of p53 protein (Cheng and Haas, 1990; Gualberto and Balwin, 1955; Gualberto et al., 1995) . Both forms have been shown as potentially capable of binding to and functionally cooperating with the Sp1 protein (Gualberto and Balwin, 1955; Gualberto et al., 1995) . Therefore, it was of interest to find out which of them participated in forming complex I. For this purpose, we repeated the supershift assays with the nuclear extract of the TPAtreated cells and oligo 4, but employed the following anti-p53 antibodies: pAb421 that recognize both w.t and mutant forms, pAb240 that recognize only the mutant form and pAb1620 antibodies that recognize only the w.t. form. The results presented in Figure 4e demonstrate that pAb421 antibodies completely shift band I and form another band (Ib). On the other hand, pAb240 and pAb1620 antibodies shift band I only partially while forming two new weaker bands; band Ib that moves to the same position as the single new band Ib formed by pAb421 and band Ia that moves only half way (approximately to the position of the new band shifted by the anti-Sp1 antibodies in Figure 4d ). These data can be explained by assuming that band I consists of a mixture of complexes containing one molecule of Sp1 protein and two molecules of p53 protein and that the two p53 molecules may both be either w.t. or mutant or one of them may be w.t. while the other molecule is mutant. Therefore, each of these combinations can bind two molecules of pAb421 antibodies and consequently be shifted to band Ib position. On the other hand, only complexes containing two mutant p53 molecules can bind two pAb240 molecules and be shifted to band Ib position, whereas those containing two w.t. p53 molecules do not bind these antibodies and are, therefore, left in their original band I position. The opposite occurs with the pAb1620 antibodies. The intermediate bands Ia formed by pAb240 and pA1620 represent complexes containing one mutant and one w.t. p53 molecule that can bind only one molecule of either of these antibodies.
TPA does not increase the cellular level of either Sp1 or p53 protein
To elucidate whether the formation of the Sp1-p53 complexes results from elevation of the cellular level of Figure 4 Gel-shift evidence for the binding of the Sp1-p53 complex to the Sp1(2) site. (a) Labeled oligo 1 (w.t. Sp1(1) þ w.t. Sp1(2)) was incubated with nuclear extracts of untreated control Jurkat cells and (b) labeled oligo 1, oligo 2 (mut Sp1(1) þ mut Sp1(2)), oligo 3 (w.t. Sp1(1) þ mut Sp1(2)) and oligo 4 (mut Sp1(1) þ w.t Sp1(2)) were incubated with nuclear extracts of Jurkat cells treated with TPA alone or together with BI for 6 h. The reaction products of (a) and (b) were subjected to EMSA. Figure 5a demonstrate that TPA does not affect the level of either of these proteins, indicating that the formation of the Sp1-p53 complexes involves a post-translational process.
DNA-independent formation of the Sp1-p53 complex
In the next experiment, we elucidated whether the Sp1-p53 complex was formed before or after binding to the target DNA site. For this purpose, Jurkat cells were treated with TPA7BI for the indicated times and their nuclear extract was immunoprecipitated with mouse monoclonal anti-Sp1 antibodies or with the mouse pAb421 anti-p53 monoclonal antibodies. Western blot analysis of the resultant immunoprecipitates with mouse anti-Sp1 and rabbit anti-p53 antibodies revealed that p53 was pulled down together with Sp1 by the anti-Sp1 antibodies and vice versa, Sp1 was pulled down together with p53 by the anti-p53 antibodies (Figure 5b ). No coprecipitation of Sp1 or p53 was detected by antialbumin antibodies (not shown), indicating the specificity of the coprecipitation with the other two antibodies. This finding, together with the results shown in Figure 5a , demonstrates that this complex is formed by association of pre-existing Sp1 and p53 molecules, which occurs prior to their DNA binding. Furthermore, BI did not prevent this association, indicating that only the binding of this complex to the Sp1(2) site, but not its formation, was mediated by a PKC-dependent mechanism.
Activation of p21
WAF-1 by TPA does not require p53-binding site p21
WAF-1 is a direct target of p53 and its promoter contains two p53-binding sites (Gartel and Tyner, 1999 ) (see Figure 3a for their location). Earlier studies with certain other cell lines (Koutsodontis et al., 2001) have shown that Sp1 and w.t p53 exert a cooperative stimulatory effect on p21 WAF-1 by forming an Sp1-p53 complex independent of any external signal. Furthermore, it has been shown that this effect is mediated by direct binding of the Sp1 component of the complex to the Sp1(3) site and of p53 component to the more distal p53-binding site residing between nucleotides À2325 and À2260. Therefore, it was of interest to find out whether any of the two p53 sites was also required for the PKC-dependent p21
WAF-1 stimulation in the Jurkat cells. To address this question, we examined, first, the consequence of inactivation of the more distal p53 site by a site-directed mutagenesis as shown in Figure 3a . This mutation was found to abolish the promoter response to w.t. p53 (data not shown), suggesting that the remaining more proximal p53 site was inactive under these experimental conditions. Nevertheless, this mutant promoter was effectively stimulated by TPA, as well as by PKC-a and PKC-e (not shown). However, it can still be argued that although the proximal p53 site does not seem to respond to w.t. p53 alone, it might, nevertheless, participate in mediating the stimulatory effect of TPA and PKC on the binding of the Sp1-p53 complex to the p21 WAF-1 promoter. Therefore, in the subsequent experiments, we examined the effect of TPA, PKC-a and PKC-e on Luc expression through the À215/ þ 8 (Figure 6 ) or the À143/ þ 8 (data not shown) fragments of the p21 WAF-1 promoter (À215/ þ 8 p21-Luc and À143/ þ 8 p21-Luc, respectively), which contained all the six Sp1 sites but none of the p53 sites (see Figure 3a) . These experiments revealed that both truncated promoters fully responded to TPA and to the two stimulatory PKCs. Together, these data indicate that no p53-binding site is required for this effect in addition to the Sp1(2) site.
Discussion
Expression of the CDK inhibitor p21
WAF-1 is regulated by a variety of external signals which exert their effect through binding sites of different transcription factors located in its promoter (Gartel and Tyner, 1999) . The present study demonstrates that TPA and the HTLV-I Tax protein stimulate p21 WAF-1 expression in both HTLV-I infected (SLB-I) and uninfected (Jurkat) human T-cell lines. When acting together, TPA and Tax Figure 5 Effect of TPA on the cellular level of Sp1 and p53 proteins and DNA-independent formation of the Sp1-p53 complex. (a) Whole-cell extracts (100 mg protein), prepared from Jurkat at the indicated time points during their treatment with TPA, were subjected to Western blot analysis with anti-Sp1 (left blot) and with pAb421 anti-p53 (right blot) antibodies. After detecting Sp1 and p53 proteins, each blot was striped and reacted with antibodies against human actin. (b) Nuclear extracts of Jurkat cells treated for 6 h with TPA alone (upper panels) or with the inhibitor BI (lower panels) were immunoprecipitated with mouse anti-p53 (pAb421) antibodies (left panels) or mouse anti-Sp1 antibodies (right panels). The immunoprecipitates were subjected to Western blot analysis. The ones obtained with the anti-p53 antibodies were analysed with rabbit anti-Sp1 (left panels) and the other with rabbit anti-p53 (right panels) antibodies. In each Western analysis, we included a sample of cell extract containing high levels of the respective protein (Sp1 in the left and p53 in the right panels) provided by the antibodies' supplier as a positive control in addition to the size markers p21 WAF-1 activation by TPA Y Schavinsky-Khrapunsky et al elicit an additive effect and when the activity of either of them is selectively blocked, the effect of the other remains unaffected. This observation indicates that each of these agents stimulates p21 WAF-1 expression by a different mechanism that does not affect the other.
While exploring the mechanism of the TPA effect on p21 WAF-1 , we noted that this effect required PKC activity, since it could be abolished by the PKC inhibitor BI. However, examination of different individual PKC isoforms revealed that they varied in their effect on p21 . While PKC-a and PKC-e stimulated its expression, PKC-Z was rather inhibitory and PKC-b1 and b2 were ineffective. It should be noted that all of these PKCs were present and could be activated by TPA in the employed cells. However, we demonstrated that when PKC-a or PKC-b was cotransfected together with PKC-Z, the effect of the stimulatory isoforms prevailed. This finding suggests that although TPA activates various PKC isoforms that individually elicit different effects on p21 , the stimulatory isoforms are dominant and override the inhibitory ones.
Previous studies from other laboratories suggest that the site through which PKC activates p21 WAF-1 expression may vary in different cell lines (Biggs et al., 1996; Zeng et al., 1997; Biggs and Kraft, 1999) . The present experiments indicate that in the Jurkat cells, the TPAactivated stimulatory PKCs exert their effect through the second most upstream Sp1 site [Sp1 (2)]. Interestingly, Koutsodontis et al. (2002) have shown that Sp1 protein cannot bind to oligo containing w.t. Sp1(1) þ mutant Sp1(2), thus supporting our conclusion about the functional importance of this particular Sp1 site. Furthermore, we found that TPA stimulates the binding of an Sp1-p53 complex to this particular Sp1 site. Detailed supershift analysis with anti-Sp1 and antip53 antibodies suggested that this complex consists of one Sp1 and two p53 molecules and that the two p53 molecules could be either w.t. or mutant p53 forms or one w.t. and the other mutant.
The tight correlation between the PKC-dependent activation of p21 WAF-1 promoter by TPA through the Sp1(2), observed in our transfection experiments and the PKC-dependent TPA-induced specific binding of the Sp1-p21 complex to the same Sp1(2) site, demonstrated by our electrophoretic mobility assays, strongly suggests that this complex mediates the TPA-induced p21
WAF-1 gene activation. To provide further evidence for the crucial role of the Sp1 and p53 proteins in this activation, we are planning additional experiments to determine whether blocking the synthesis of these proteins by the RNA-interference approach (Yang, 2003 ) will or will not abolish this effect.
A previous report has shown that overexpression of w.t. p53 protein induces, in certain cell lines, the formation of an Sp1-p53 heterocomplex that cooperatively stimulates p21
WAF-1 expression independent of any external signal (Koutsodontis et al., 2001) . Furthermore, this cooperation has been shown to require the interaction of the complex with both the Sp1(3) and the distal p53 sites. In contrast, our present experiments revealed that the Sp1-p53 complex, mediating the TPAinduced stimulation of p21 WAF-1 in Jurkat cells, contains both w.t. and mutant forms of p53 protein and that its formation did not result from overexpression of either p53 or Sp1 proteins. Furthermore, this complex exerted its effect in the Jurkat cells through the Sp1(2), rather than the Sp1(3) site and it could be demonstrated with truncated p21
WAF-1 promoters containing only the six Sp1 sites but none of the two p53 sites, indicating that there was no involvement of p53-specific binding site in this effect. These variations suggest that p21 WAF-1 expression can be modulated by the same or similar transcription factors through different mechanisms that are presumably cell type dependent.
In previous studies, we have demonstrated that TPA induces apoptosis and activates the expression of HTLV-I LTR in Jurkat cells. However, the onset of both effects was delayed until the cells were depleted of PKC activity (Torgeman et al., 2001a) . This coordination between the two effects can be partially explained by the results of the present study on the basis of the following reported information: elevation of p21 protein frequently precedes the onset of apoptosis induced by DNA damage and certain other stress conditions (Blatt and Glick, 2001 ). This elevated p21 WAF-1 delays the onset of apoptosis and facilitates DNA repair, thus giving the cells the opportunity to avoid DNA damage and to prevent its entrance into the apoptotic death process. If the stress-causing factor is excessive or unremovable, then apoptosis can start , but this occurs only after p21 WAF-1 protein is degraded by caspases (Gorospe et al., 1996 (Gorospe et al., , 1997 (Gorospe et al., , 1998 (Gorospe et al., , 1999 Gervais et al., 1998; Zhang et al., 1999; Jin et al., 2000) . On this ground, it can be proposed that the PKC-induced elevation of p21 , observed in our present study, may likely account for the delay in the onset of apoptosis noted in our previous study (Torgeman et al., 2001a) . In addition, the TPA-induced activation of HTLV-I LTR noted in our previous study, was shown to involve binding of the same Sp1-p53 complex to an Sp1 site residing in the viral LTR, but this binding was found to be antagonized by PKC activity (Torgeman WAF-1 -Luc was transfected into Jurkat cells, pretreated with TPA for 6 h or cotransfected together with either p53-, PKC-a-or PKC-e-expressing plasmids. Untreated cells transfected with the reporter plasmid alone served as control. Luc activity and normalization to transfection efficiency were as described in Figure 1 p21 WAF-1 activation by TPA Y Schavinsky-Khrapunsky et al et al., 2001b) . It is quite possible that this antagonism results from a certain PKC effect that increases the affinity of this complex towards the Sp1(2) of the p21 WAF-1 promoter, while concomitantly reducing its affinity to the Sp1 site of the viral LTR. This implies that the activation of PKC and its subsequent downregulation direct a shuttle of the Sp1-p53 complex between the Sp1 sites of the p21 WAF-1 promoter and the viral LTR and that this shuttle coordinates the simultaneous onsets of both apoptosis and the LTR activation. We are presently conducting more detailed experiments to confirm this linkage and to elucidate its molecular mechanism.
Materials and methods
Cells
In this study, we used the SLB-I (HTLV-I infected) and Jurkat (uninfected) T-cell lines. The cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum, glutamine and antibiotics.
Plasmids and transient transfection assay
The plasmid expressing the HTLV-I Tax protein through the hCMV promoter (designated by us as pCMVTax) was generously provided by Francoise Bex (Laboratore de Microbiologie, Universite Libre de Bruxelles, B-1070, Brussels, Belgium). The plasmid expressing the truncated Tax mutant D58 Tax has been described elsewhere (Gitlin et al., 1991; Torgeman et al., 2001a) . The plasmid pc53-SN3 expressing w.t. p53 through the hCMV promoter, as well as the plasmids expressing luciferase through the w.t. p21 WAF-1 promoter or p21 WAF-1 promoters with different mutations, each inactivating a different Sp1-binding site or through the À215/ þ 8 and À143/ þ 8 fragments of the p21 WAF-1 promoter (À215/ þ 8 p21-Luc and À143/ þ 8 p21-Luc, respectively), were kindly provided by Dimitris Kardassis (University of Crete Medical School, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology of Hellas, Herakolion, GR-71110, Greece). In addition, we introduced into the w.t. p21
WAF-1 promoter a mutation impairing its distal p53-binding site located between nucleotides À2281 and À2268 relative to the transcription starting point (ElDeiry et al., 1993; Koutsodontis et al., 2001) , using the 'GeneEditor TM in vitro Site-Directed Mutagenesis System' kit purchased from Promega (see Figure 3a for the location of the six Sp1 and two p53 sites and the corresponding inserted mutations, as well as the À215/ þ 8 and À143/ þ 8 fragments of the promoter). The plasmids pZLPKC-a, pZLPKC-b1, pZLKC-b2, pZLPKC-e and pZLPKC-Z, expressing constitutively active forms of the respective PKCs through the MoMuLV LTR (Eldar et al., 1990; Livneh et al., 1996) were provided by Etta Livneh from our department. The plasmids were transfected into the indicated target cells by electroporation as previously described (Revazova et al., 1995) . A plasmid expressing b-galactosidase through MoMuSV LTR (MSV-b-gal, 1 mg) was used to assess the relative transfection efficiency. The enzymatic activities were assayed in the cell extracts at 48 h after transfection and the luciferase activity was normalized according to the b-gal activity and expressed as fold of the relevant control of each experiment.
Antibodies
Mouse monoclonal antibodies against p21 , Sp1, albumin, PKC-a, PKC-b1, PKC-b2, PKC-e, PKC-Z, rabbit anti-p53 (recognizing both the w.t. and mutant forms of p53), mouse anti-rabbit-IgG and rabbit anti-mouse-IgG antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), whereas mouse anti-human actin monoclonal antibodies were obtained from ICN Biomedicals Inc. (OH, USA). Mouse anti-human p53 monoclonal antibodies clone pAb420 (recognizing both the w.t. and mutant forms of p53), clone pAb240 (recognizing only mutant forms of p53) and clone pAb1620 (recognizing only the w.t. form of p53) were provided by Varda Rotter (Weizman Institute of Science, Rehovot, Israel).
Treatment of cells with TPA-and PKC-specific inhibitor TPA (Sigma Chemicals Israel Ltd, Holon, Israel), dissolved in DMSO (Sigma), was added to cell cultures at a final concentration of 50 nm. Control cells received the same volume of DMSO. When indicated, the PKC-specific inhibitor bisindolylmaleimide GF 109203X (BI, Sigma) (Toullec et al., 1991) was added to the cultures at a final concentration of 2 mm 1 h before TPA to ensure its penetration into the cells before PKC activation. Unless otherwise specified, these treatments were carried out for 6 h after TPA addition.
Western blot analysis of p21
WAF-1 and PKC isoforms Whole-cell extract (100 mg protein) of the TPA-treated and untreated SLB-I and Jurkat cells were analysed for the level of p21 WAF-1 protein by Western blot as previously described (MorVaknin et al., 1997), using anti-p21 WAF-1 monoclonal antibodies. Similar analysis was employed to measure the level of the Sp1 and p53 proteins and of the various PKC isoforms in extracts of cells treated with TPA for the indicated increasing times, using the monoclonal antibodies recognizing the indicated proteins. When specified, TPA treatment was performed in the presence of the PKC inhibitor BI. For initial assessment of equal protein loading of the different samples, the proteins migrating in the different lanes were visualized by staining the blotted filter with Ponceau S reagent before reacting it with the antibodies. In addition, after detecting the specific proteins, each filter was striped from the initial antibodies and reacted with anti-human actin antibodies for loading reassessment.
Preparation of nuclear extracts
Nuclear extracts were prepared from 10 7 cells as previously described (Torgeman et al., 1999 (Torgeman et al., , 2001b and were stored in small aliquots at -701C until use.
Electrophoretic mobility shift assay (EMSA)
The following oligonucleotides were used: The underlined nucleotides are the w.t. Sp1(1) and w.t. Sp1(2) sites (from 5 0 to 3 0 ) and the bold nucleotides are the p21 WAF-1 activation by TPA Y Schavinsky-Khrapunsky et al substitutions made for generating the mut Sp1(1) and mut Sp1(2) sites. The oligonucleotides were labeled by filling-in with the Klenow fragment of DNA polymerase-I and [a-P 32 ]dCTP as detailed elsewhere (Gitlin et al., 1991) and used as probes (1 ng, B5 m10 4 cpm) for DNA-binding assay of nuclear proteins (15 mg in 30 ml final reaction volume) as previously described (Torgeman et al., 1999 (Torgeman et al., , 2001b .
For supershift analysis, the indicated monoclonal antibodies (1 mg) were added together with the labeled probe. For negative control, we employed irrelevant antibodies such as the anti-albumin monoclonal antibodies.
For immuno coprecipitation assays, aliquots of the tested nuclear extracts (200 mg protein) were immunoprecipitated with 20 mg of the indicated antibodies and the immunoprecipitates were collected by protein A-Sepharose beads. The precipitated proteins were dissociated from the beads by heating at 951C for 5 min and then subjected to Western blot analysis with the indicated antibodies as previously described (Torgeman et al., 1999 (Torgeman et al., , 2001b .
